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Intrace|lular  protozoa,  Leishmania  spp,  Trypanosoma  cruzi,  and  Toxoplasma 
gondii,  have as a  pathogenic  characteristic  a  particular  tropism for host mono- 
nuclear phagocytes. Successful invasion of host macrophages (M4~)  1 by Leishmania 
promastigotes requires an initial interaction at the cell surface that has not been 
defined. In the presence of serum, enhanced binding ofLeishmania promastigotes 
to murine resident peritoneal  M~b (RPM) is mediated by complement (1). In the 
absence of serum,  the  lectin-like  Mq~-specific mannosyl/fucosyl receptor (MFR) 
may play a  role  (2),  consistent  with  studies  (3,  4)  demonstrating  mannose-rich 
glycoconjugates  on  the  surface  of L.  donovani  promastigotes.  We  report  an 
additional  role  for  the  type  three  complement receptor  (CR3)  in  serum-inde- 
pendent binding ofL. donovani to RPM. Modulation experiments in which either 
CR3 or MFR are rendered inaccessible demonstrate that both receptors must be 
present  on  the  segment  of M4~  membrane  to  which  the  parasite  binds.  The 
combined function  of these two distinct  M4~ receptors  may represent a  general 
mechanism for the entry of pathogenic protozoa into mononuclear phagocytes. 
Materials and  Methods 
Mice.  C57BL/10ScSn mice were from OLAC(1976) Ltd., Bicester, Oxon, or bred at 
the London School of Hygiene and Tropical Medicine and males or females used between 
6 and 12 wk. 
Reagents.  The rat anti-mouse CR3 monoclonal antibody (mAb) Ml/70  (anti-Mac-l) 
(5) was used at saturation (6).  Fab fragments of M1/70 and rat anti-mouse mAb 2.4G2, 
which binds to Mq~ IgG2b/IgG  1 Fc receptors (7),  were kind gifts from Dr. T. Springer, 
Harvard Medical School, Boston and Dr. J.  Unkeless, The Rockefeller University, New 
York.  F4/80,  a  rat  antibody  (Ab)  specific  for  mature  mouse  M4~  (8),  was  used  as 
concentrated hybridoma supernatant. Anti-C3 Fab, prepared from a rabbit anti-human 
C3 that crossreacts with mouse C3,  was used at a concentration (200 t~g/ml)  known to 
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block all lymphocyte CR1 and CR2 rosetting (9). The nucleophile, sodium salicyl hydrox- 
amate, was prepared as a  100  mM solution in  100  mM NaOH and diluted in culture 
medium to  1 mM. Mannan (M7504) and ribonuclease B (type XIIB) (both from Sigma 
Chemical Co., St. Louis, MO) were used as MFR inhibitors at 1 mg/ml. 
Parasites.  Details of the isolation of L. donovani amastigotes from hamster spleen, and 
of the transformation and culture of promastigotes, appear elsewhere (2). Promastigotes 
were used between days 3 and 7 of the 3rd to 17th subcultures, as indicated. 
Mouse M4~.  RPM were plated on washed,  13-mm  glass coverslips  (2) or on M1/70-, 
M 1/70-Fab-, mannan-, or 2.4G2-Fab-coated coverslips prepared by the method of Michl 
et al. (10). The ability of Mq~ on coated coverslips to rosette iC3b-coated erythrocytes was 
assessed microscopically. Assays of 125I-mannose-bovine serum albumin uptake or M 1/70 
binding by M4~ on mannan- or M 1/70-Fab-coated coverslips have been described (6). 
Parasite/Mck  Binding.  In  each  experiment,  5  x  10°promastigotes  or  2.5  x  106 
amastigotes were added to two or four coverslips,  which were then washed and examined 
after 20  min.  M4~ were  scored individually (300-500  per coverslip)  for attached and 
ingested parasites from Giemsa-stained fixed preparations (2). M4~ were preincubated with 
soluble inhibitors for 15 min before and during the parasite incubation. Parasite binding 
to M4~ was examined in the absence of serum or with 8-12% normal or heat-inactivated 
(56°C, 30 rain) mouse serum (NMS or HINMS). 
Alternative  Pathway Activation.  Consumption of complement in fresh human serum by 
promastigotes, amastigotes, and zymosan was compared (per parasite or particle) by a 
two-stage assay (11). Alternative pathway activation was also measured for mannan (6.25 
rag/m  l), parasites in the presence of mannan (6.25 mg/ml), and mannan-coated coverslips. 
Results and Discussion 
The role of locally secreted complement proteins in mediating binding to Mq~ 
CR3  has  already been  established  for  the  yeast wall  product  zymosan (6).  In 
initial experiments we examined the effects of the monoclonal anti-CR3 Ab M 1/ 
70  on  serum-independent  binding and  ingestion  of L.  donovani  promastigotes 
and amastigotes by RPM. Fig. 1 A shows one experiment representative of 15 in 
which binding efficiency for control  M4~ was 30-260  parasites per  100  cells in 
20 min, depending on the promastigote subculture used, and for which 53-88% 
inhibition of promastigote binding and ingestion was observed in the continuous 
presence  of soluble  M1/70.  In  control  experiments,  similar inhibition of pro- 
mastigote  binding  was  obtained  after  preincubation  alone  with  M1/70.  The 
unrelated Ab F4/80 caused no inhibition of promastigote binding. It is unlikely, 
therefore,  that  the  inhibition  observed  with  M1/70  was  simply due  to  steric 
hindrance.  In four parallel experiments with amastigotes, binding efficiency in 
control  Mq~ was  130-320  parasites per  100  cells in  20  min, but only 14-43% 
M1/70  inhibition was observed.  This difference in  ability to block binding of 
pro- and amastigotes with M 1/70 correlated with their relative abilities to activate 
the  alternative  pathway  (Fig.  1B)  and  was  mimicked  by  the  use  of the  Fab 
fragment of anti-C3  Ab  or the  nucleophile,  sodium salicyl hydroxamate (Fig. 
I A). Sodium salicyl hydroxamate is a potent inhibitor of the covalent binding of 
activated C3 to the activator surface (12), providing strong evidence that cleaved 
C3, in the degraded iC3b form, on the surface of promastigotes mediates binding 
to  CR3.  Under  similar  assay  conditions  we  have  recently  shown  by  sodium 
dodecyl sulfate-polyacrylamide gel analysis that M4~-derived cleaved C3  (iC3b) 
can be deposited on zymosan in the absence of exogenous complement (6 and 
Ezekowitz and Sim, unpublished results). 
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FIGURE  1.  (A) One experiment in which the effect of blocking Me CR3 activity using soluble 
M1/70  is compared  with inhibition due  to an anti-C3  Fab antiserum and  the nucleophile, 
sodium salicyl hydroxamate (S.S.H.) for both promastigotes (day 7, subculture 3) and amasti- 
gotes of L.  donovani examined on the same day.  In this experiment, parasite binding in the 
absence of serum was 45 -  8 promastigotes and 264 -+ 22 amastigotes per  100 cells per 20 
min for control MS. The graph shows percent inhibition of parasite binding calculated for the 
16 possible individual coverslip comparisons (~ -  SD)  made between quadruplicate treated 
and control coverslips. (B) The ability of promastigotes (day 4, subculture 8) and amastigotes 
to consume the alternative pathway is compared with the known activator zymosan. 
of locally iC3b-opsonized promastigotes to the M~b surface. In view of our earlier 
observation (2) of MFR-mediated promastigote binding to RPM, we have deter- 
mined the relative roles of these two receptors in parasite binding. A  role for 
the MFR in uptake of zymosan has been demonstrated (13) and, in different M4) 
populations, additive effects of receptor blocking with mannan plus M 1/70 were 
observed (6). In the present experiments (Fig. 2), the use of mannan or ribonu- 
clease  B  as  soluble  inhibitors  of  MFR-mediated  binding  resulted  in  similar 
inhibition to that with M1/70:  promastigotes, 50-80%,  amastigotes, ~30%.  In 
no case was there any evidence for an additive effect of blocking the two receptors 
simultaneously. Mannan (6.25 mg/ml) did not itself consume alternative pathway 
components  or  inhibit  the  ability  of the  parasite  to  activate  the  alternative 
pathway. It was unlikely, therefore, that the effects of mannan or ribonuclease 
B were due to interference with or inhibition of CR3-mediated binding of the BLACKWELL ET  AL.  327 
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FIGURE 2.  Effects  of soluble inhibitors on CR3- and MFR-mediated uptake of L.  donovani 
promastigotes (days 5 and 6, subcultures 10 and 6) and amastigotes by RPM. Results show 
percent inhibition of parasite binding in independent experiments examining (i)  M1/70, 
mannan, or M  1/70 + mannan, and (ii) M 1/70, ribonuclease B (rib-B), or M  1/70 + ribonucle- 
ase B. Numbers in brackets are the ~ -  SD parasites per 100 cells per 20 rain for control MS. 
parasite.  Rather,  it  appeared  that  each  receptor  played an  equivalent role  in 
binding and ingestion of the parasite. 
One explanation for the link between CR3 and MFR could be that they act 
sequentially, one receptor mediating attachment and the other promoting inter- 
nalization. Our method of scoring parasites associated with MqS did not always 
allow  us  to  distinguish  these  two  functions.  To  clarify the  roles  of the  two 
receptors,  we performed additional experiments in which CR3 and MFR were 
selectively modulated onto M 1/70-Fab- or mannan-coated coverslips. M~b plated 
on M 1/70-Fab coverslips were unable to rosette iC3b-coated erythrocytes; spe- 
cific binding of M 1/70 was <10%  compared with M~b plated directly onto glass 
(12,133  ±  416  cpm 125I-labeled second stage Ab per coverslip). Specific uptake 
of 125I-mannose-BSA was equivalent to that of control M4) (6,980  ±  198  cpm/ 
coverslip during 20 min at 37°C). In the reciprocal experiment with cells plated 
on mannan-coated coverslips, iC3b-erythrocyte rosetting and binding of M 1/70 
(12,600 ±  1,414 cpm/coverslip) was equivalent to that of control MqS, but uptake 
of ~25I-mannose-BSA was reduced by 71%.  These experiments established that 
CR3  and  MFR are  distinct receptors  whose function can  be  modulated inde- 
pendently. In experiments with parasites (Fig. 3), equivalent reduction in binding 
and  ingestion  by  M4~  was  observed  after modulation of either  CR3  or  MFR: 328  CR3  1N  SERUM-INDEPENDENT  BINDING  OF  LEISHMANIA 
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FIGURE 3.  The effect of modulation of CR3 and MFR onto M1/70-Fab- and mannan-coated 
coverslips (CS) on serum-independent  binding ofL. donovani promastigotes (days 3-7, subcul- 
tures 5-17) and amastigotes by RPM. The graph shows percent inhibition (~ + SD) of total 
parasite binding (attached plus ingested) over five independent experiments for M@ on coated 
coverslips with or without the addition of M 1/70 or mannan (1 mg/m]) as soluble inhibitors. 
Parasite binding by control Me was 202-265 promastigotes and 300-340 amastigotes per 100 
M4~ per 20 min. 
promastigotes, ~80%, amastigotes, -60%.  The addition of soluble inhibitors did 
not, in either case, enhance the inhibition.  In control experiments, no inhibition 
of parasite binding was observed for M4~ where IgG2b/IgG 1 Fc receptors were 
modulated onto 2.4G2-Fab-coated coverslips, and mannan-coated coverslips did 
not activate the alternative pathway. 
These experiments demonstrate that, under serum-free conditions, both CR3 
and  MFR  are  required  to  promote  attachment  and  ingestion  of the  parasite. 
Neither  receptor  alone  is  capable  of performing  even  the  lesser  function  of 
parasite attachment.  Hence, an hypothesis based on sequential action of the two 
receptors is precluded,  since at least one of them would be expected to bind the 
parasite.  Nor  does  it appear  that  the  remote  signalling  mechanisms described 
(14)  for  the  combined  action  of  fibronectin  and  complement  receptors  are 
operating.  In that  system, stimulation  of the  basal surface of monocyte plasma 
membranes by substrate-bound fibronectin was sufficient to activate complement 
receptors on the remote apical surface of the cell.  In our studies,  interaction  of 
either  CR3  or MFR  with  its respective surface-bound  substrate (M1/70-Fab  or BLACKWELL  ET  AL.  329 
mannan) was not sufficient to promote attachment and ingestion by the receptor 
accessible to  the  parasite  on  the  upper  surface  of the  M4). Apparently,  both 
receptors must be present on  the segment of membrane  to which the parasite 
binds.  This  suggests  some  form  of conformational  co-recognition  mechanism 
such as might occur if the same glycoconjugate molecule on the parasite surface 
were involved both in activating complement and in binding to MFR. Although 
earlier  studies (3,  4) have shown mannose-rich  glycoconjugates on the parasite 
surface, the covalent binding of activated C3 may be required to cause a necessary 
conformational change in the molecule, exposing the sugar residues that bind to 
MFR. As the MFR binds to this portion of the molecule, it may, in turn, promote 
maximal  presentation  of the binding site of iC3b to CR3. Further  experiments 
are required to test these hypotheses. 
As shown by others (1) fresh serum can enhance the binding of promastigotes 
of other species of Leishmania  by M4). In experiments with L.  donovani we also 
observed dramatic increases in total promastigote binding to M~b in the presence 
of NMS. For example, control M4) bound or ingested 260 +  8 promastigotes per 
100 M4) during 20 min in the absence of serum,  1,095 _+ 95 in the presence of 
8% NMS, and 438 +  78 in the presence of 8% HINMS. In the same experiment, 
320 +  28 amastigotes per 100 Mq~ during 20 rain were bound or ingested in the 
absence of serum,  235  _+  71  with  8%  NMS, and  184  +  15  with  8%  HINMS. 
Hence, for amastigotes there was no serum-induced enhancement of binding. In 
these experiments, inhibition of promastigote binding (Fig. 4) using soluble M 1/ 
70, anti-C3  Fab, or sodium salicyl hydroxamate,  or using M1/70-coated cover- 
slips, was higher (70-95%) than that observed with soluble mannan or mannan- 
coated coverslips (~35%). A larger proportion of the enhanced serum-dependent 
binding of promastigotes can therefore be accounted for by the activity of CR3, 
which in this case functions at least partially independently of the MFR. 
In  this  study we have  shown  that  M4)-derived complement  components are 
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FIGURE 4.  Effect of M4) receptor inhibition or modulation on serum-dependent binding of 
L. donovani  promastigotes. The graph shows percent inhibition (~ +  SD) of promastigote (day 
7,  subcultures  8 and  3) binding obtained  in two independent experiments using (i)  soluble 
M 1/70, soluble mannan, mannan-coated coverslips (CS), or 2.4G2-Fab-coated coverslips, and 
(ii)  M1/70-coated  coverslips, soluble  MI/70,  anti-C3  Fab,  and  sodium  salicyl  hydroxamate 
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sufficient to mediate local opsonization of Leishmania  and binding to CR3 that, 
in the absence of serum, requires the presence of an additional M4~ receptor, 
MFR. Although the precise  mechanism for the combined action of these two 
receptors is not understood, the constitutive ability of M~ to produce complement 
components may play an important role in recognition and uptake of this and 
many other parasites known to activate the alternative pathway. 
Summary 
We have examined the relative roles of the macrophage (M40 plasma mem- 
brane receptor for the cleaved third complement component (iC3b, CR3) and 
of the mannosyl/fucosyl receptor (MFR) in binding and ingestion of Leishmania 
donovani.  In the absence of exogenous complement, the binding and ingestion 
of promastigotes,  which  are  good  activators  of the  alternative  complement 
pathway, were inhibited by the anti-CR3 monoclonal antibody M1/70,  by the 
Fab  portion  of an  anti-C3  antibody,  or  by  the  nucleophile,  sodium  salicyl 
hydroxamate, an inhibitor of C3  fixation. This provides strong evidence that 
Mq~-derived,  cleaved C3  (iC3b)  present  on the  promastigote surface mediates 
binding to CR3. Equivalent inhibition of promastigote binding and ingestion was 
also observed using the soluble inhibitors of MFR activity, mannan or ribonucle- 
ase B. No additive effect for blocking the two M4~ receptors simultaneously was 
observed. For amastigotes, which are poor activators of the alternative pathway, 
a  lesser but  nevertheless equivalent effect was  observed for the three soluble 
inhibitors  of CR3-mediated  binding  vs.  the  two  soluble  inhibitors  of MFR- 
mediated binding.  Modulation experiments in which either CR3  or MFR had 
been rendered inaccessible demonstrated that both receptors must be present 
on the segment of M4~ membrane to which the parasite binds.  The combined 
function of these two distinct M4~ receptors may provide a  general mechanism 
for recognition and ingestion of other pathogenic protozoa known to activate 
the alternative pathway. 
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